Molecularly targeted therapy: when to stop and when to continue?
Hirsch
Fred R
FR
Mok
Tony S
TS
Borges
Virginia
V
Bunn
Paul A
PA
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D016903:Drug Monitoring; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D066246:ErbB Receptors; D047428:Protein Kinase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human